Navigation Links
OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation
Date:3/21/2011

jailed diagonal branch, which are recognized risk factors for stent thrombosis. It also revealed discrepancies in the reported data and inconsistencies and misrepresentations in the study and the reporting of the study. Upon presentation of the findings of the independent evaluation, Dr. Cervinka admitted that he had made mistakes; however, changes which he made to subsequent presentations and the publication of the study in a medical Journal did not correct the reporting of the defects in the study, nor admit nor publish the errors and invalidity of the study.

Dr. Cervinka presented the results and conclusions of the study a number of times after he and the Masaryk Hospital were made aware of the defects in the study and the study reporting. As a result of the wide dissemination of the study and its erroneous conclusions that were not supported by the data, numerous clinicians stopped using the product and terminated clinical trials, and OrbusNeich suffered reputational damage.  Despite many requests by OrbusNeich, neither Dr. Cervinka nor the Masaryk Hospital has made public disclosure of the defects or deficiencies in this invalid study.

Alfred J. Novak, Chairman and Chief Executive Officer of OrbusNeich, said, "OrbusNeich stents and its other products provide innovative therapies that improve the lives of patients around the world.  We have taken this action only after many unsuccessful attempts to try to work with Dr. Cervinka and the Masaryk Hospital to correct the record.  We informed Dr. Cervinka and the Masaryk Hospital about the inaccuracies, misrepresentations and inconsistencies that were unveiled by an independent reviewer of the study, and they acknowledged our position. Nevertheless Dr. Cervinka and Masaryk Hospital continued to widely present and publish the flawed and invalid study, resulting in damages to OrbusNeich's business and reputation.  While we attempted to resolve this issue amicably, the actions by Dr. C
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
2. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
3. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
4. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
5. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
6. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
10. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
11. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... 2, 2011 Omnicell, Inc. (NASDAQ: OMCL ), a ... today announced results for its first quarter ended March 31, 2011. ... quarter of 2011 was $57.2 million as compared with $57.3 ... million or 5.5% from the first quarter 2010 revenue of ...
... (Hologic or the Company) (Nasdaq: HOLX ), a ... imaging systems and surgical products dedicated to serving the healthcare ... fiscal quarter ended March 26, 2011. ... $438.7 million. Net income was $82.4 million, or $0.31 ...
Cached Medicine Technology:Omnicell Announces First Quarter 2011 Results 2Omnicell Announces First Quarter 2011 Results 3Omnicell Announces First Quarter 2011 Results 4Omnicell Announces First Quarter 2011 Results 5Omnicell Announces First Quarter 2011 Results 6Omnicell Announces First Quarter 2011 Results 7Omnicell Announces First Quarter 2011 Results 8Omnicell Announces First Quarter 2011 Results 9Omnicell Announces First Quarter 2011 Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 2Hologic Announces Second Quarter Fiscal 2011 Operating Results 3Hologic Announces Second Quarter Fiscal 2011 Operating Results 4Hologic Announces Second Quarter Fiscal 2011 Operating Results 5Hologic Announces Second Quarter Fiscal 2011 Operating Results 6Hologic Announces Second Quarter Fiscal 2011 Operating Results 7Hologic Announces Second Quarter Fiscal 2011 Operating Results 8Hologic Announces Second Quarter Fiscal 2011 Operating Results 9Hologic Announces Second Quarter Fiscal 2011 Operating Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 11Hologic Announces Second Quarter Fiscal 2011 Operating Results 12Hologic Announces Second Quarter Fiscal 2011 Operating Results 13Hologic Announces Second Quarter Fiscal 2011 Operating Results 14Hologic Announces Second Quarter Fiscal 2011 Operating Results 15Hologic Announces Second Quarter Fiscal 2011 Operating Results 16Hologic Announces Second Quarter Fiscal 2011 Operating Results 17Hologic Announces Second Quarter Fiscal 2011 Operating Results 18
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the ... the business has introduced its new collection of 2015 ... , The new prom outfits are guaranteed to contain ... They are specially designed for 2015. Anyone who wants ... visit its website before Jan. 26, 2015, the deadline ...
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... disorders may be linked to other medical problems including ... and psychiatric problems. ,Researchers conducted a study and ... had ADD. Results also show a high degree of ... of these patients also suffered severe memory impairment, depression, ...
... that giving adolescent girls estrogen treatments to keep them from ... on in life . Estrogen is thought to limit height ... women who had been assessed for estrogen therapy as girls ... had actually been treated with estrogen, and the other half ...
... 60 are affected by Parkinson’s disease. The condition is characterized ... from loss of facial rigidity // and a shuffling walk. ... of Parkinson’s disease may also be able to stop its ... found to completely halt the neurotoxic effects of a chemical ...
... study finds growth patterns in childhood can help predict which ... link a high birth weight, reaching peak growth at an ... having a low body mass index (BMI) at age 14, ... likelihood of the disease. ,For the study researchers used ...
... researchers suggest that the risk factors for heart attacks may ... studied, about two-thirds had at least one risk factor for ... of risk factors known as metabolic syndrome. One in three ... has been identified as a risk for heart disease and ...
... the number one cause of cancer death worldwide, accounting for ... disease is hard to detect in early and treatable stages, ... Studies have shown CT scans can identify the disease in ... lung cancer, but they also identify many noncancerous lesions in ...
Cached Medicine News:
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight....
3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: